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ABSTRACT
Objectives: Previous studies on the effect of statin
adherence on cardiovascular events in the primary
prevention of cardiovascular disease have adjusted for
time-dependent confounding, but potentially
introduced bias into their estimates as adherence and
confounders were measured simultaneously. We aimed
to evaluate the effect when accounting for time-
dependent confounding affected by previous adherence
as well as time sequence between factors.
Design: Retrospective cohort study.
Setting: Finnish healthcare registers.
Participants: Women aged 45–64 years initiating
statin use for primary prevention of cardiovascular
disease in 2001–2004 (n=42 807).
Outcomes: Acute cardiovascular event defined as a
composite of acute coronary syndrome and acute
ischaemic stroke was our primary outcome. Low-
energy fractures were used as a negative control
outcome to evaluate the healthy-adherer effect.
Results: During the 3-year follow-up, 474 women
experienced the primary outcome event and 557 suffered
a low-energy fracture. The causal HR estimated with
marginal structural model for acute cardiovascular events
for all the women who remained adherent (proportion of
days covered ≥80%) to statin therapy during the
previous adherence assessment year was 0.78 (95% CI:
0.65 to 0.94) when compared with everybody remaining
non-adherent (proportion of days covered <80%). The
result was robust against alternative model
specifications. Statin adherers had a potentially reduced
risk of experiencing low-energy fractures compared with
non-adherers (HR 0.90, 95% CI 0.76 to 1.07).
Conclusions: Our study, which took into account the
time dependence of adherence and confounders, as well
as temporal order between these factors, is support for
the concept that adherence to statins in women in
primary prevention decreases the risk of acute
cardiovascular events by about one-fifth in comparison
to non-adherence. However, part of the observed effect
of statin adherence on acute cardiovascular events may
be due to the healthy-adherer effect.
INTRODUCTION
Several population-based studies have investi-
gated associations between adherence to
statin therapy, defined typically as proportion
of days covered1 (PDC) or medication pos-
session ratio1 (MPR) ≥80%, and cardiovascu-
lar morbidity in primary prevention of
cardiovascular disease (CVD).2–8 Uniformly,
these studies have reported reductions in the
risk of cardiovascular events in association
with adherence when compared with non-
adherence. Previous studies have also shown
that patients’ adherence to statin therapy
varies over time,7 9 and transitions to lower
adherence levels may be associated with an
increased risk of cardiovascular events.7 Our
recent study examined adherence with two
different approaches: first as a fixed variable
measured during the first year since initi-
ation and second as a time-dependent vari-
able measured at 1-year intervals since
therapy initiation; comparable reductions in
the risk of various cardiovascular events were
observed with both approaches.8
Strengths and limitations of this study
▪ Large population-based register study covering
all female statin initiators in primary prevention
of cardiovascular disease in 2001–2004.
▪ This study expanded on previous studies by
allowing for time dependence of adherence and
confounders as well as accounting for time-
dependent confounders which could have been
affected by previous adherence.
▪ Sensitivity analyses to account for a potential
selection bias as well as healthy-adherer effect
were conducted.
▪ Data on some important confounders, such as
cholesterol level and smoking, were not available
to us.
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Most prior studies have used cohort5–8 and nested
case–control designs2–4 to assess the effect of adherence
on cardiovascular morbidity. Typically, adherence has
been measured as a single, fixed average throughout the
follow-up.2–6 As follow-up periods have varied from 3 to
12 years at maximum, very different adherence patterns
may have led to the same values of PDC or MPR.2–6
Confounders have been assessed at baseline and some
also time-dependently during the follow-up, that is,
during the same period as adherence.2–6 Consequently,
the values of these confounders (eg, switching to a more
potent statin in this case) may have been affected by
prior adherence. Conditioning on intermediate variables
that lie on the causal pathway between adherence and
outcome blocks some of the adherence effect, and may
introduce a collider-stratification bias if there are
unmeasured confounders that predict both the inter-
mediate variable and the outcome.10 11 In addition, one
major concern in observational studies is
healthy-adherer bias emerging from differences in
unmeasured health-seeking behaviours between the
groups to be compared.12–14 Employment of negative
control outcomes that reflect unhealthy behaviours
unrelated to medication effect is one way to evaluate the
role of such bias in the study results.15
Inverse probability of treatment weighted estimation
of marginal structural models (MSMs) can be employed
to overcome the problems caused by time-dependent
confounding affected by prior exposure in observational
studies.10 16 17 This study employed the MSM approach
to extend previous studies by now accounting for time-
dependent confounding affected by prior adherence
when estimating the effect of statin adherence on the
incidence of acute cardiovascular events. We compared
the results with those obtained with conventional
models. We accounted for the time-varying nature of
adherence by measuring it in yearly periods, and
adjusted for several time-dependent confounders. In
addition, we used low-energy fractures as the negative
control outcome to examine the impact of unmeasured
confounding on the effect estimates.
METHODS
The data originated from multiple administrative health-
care registers. The Finnish Prescription Register main-
tained by the Social Insurance Institution (SII)
catalogues information on reimbursed medications,
such as dispensing date, Anatomical Therapeutic
Chemical (ATC) classification code,18 strength and the
quantity dispensed, for all Finnish residents. The Special
Reimbursement Register, also maintained by the SII,
contains information on entitlements to higher medica-
tion reimbursement due to specific chronic diseases
such as diabetes and coronary heart disease (CHD).
Patients staying at public nursing homes or hospitalised
for over 90 consecutive days are not eligible for reim-
bursement, and their purchases are not registered.
These long-term institutionalised patients can be identi-
fied from a separate SII register. The Finnish Care
Register maintained by the National Institute for Health
and Welfare covers all Finnish hospitals and includes
information on primary and secondary discharge diag-
noses, surgical procedures and admission and discharge
dates. The 10th revision of the International
Classification of Diseases (ICD-10) was in use during the
study period. Statistics Finland compiles information
from many sources such as the Register of Completed
Education and Degrees, the Population Information
System of the Population Register Centre, and the
Finnish Tax Administration. All register data were linked
using personal identification numbers unique to every
Finnish resident.
Ethics, consent and permissions
Permissions were obtained from the register holders (the
SII, the National Institute for Health and Welfare, and
the Statistics Finland). Ethical approval was not needed
as we did not contact the patients and used de-identified
data. No written consent was required nor sought.
Study population
A cohort of women initiating statins (ATC codes:
C10AA01-C10AA07) in 2001–2004 and aged 45–64 years
was created from the Prescription Register. A new user
was defined as an individual who had not been dis-
pensed with statins in the time period after 1994, when
the register was established. The date of the first statin
purchase was defined as the cohort entry date. Patients
who were long-term institutionalised within 3 years prior
to or at statin initiation were excluded as were those
whose first purchase was cerivastatin (C10AA06), a medi-
cation withdrawn from the market in 2001.
Furthermore, in order to identify those women who
initiated statin therapy for primary prevention of CVD, we
excluded all patients for whom there was evidence of ath-
erosclerotic CVD in the registers. More specifically, we
excluded patients who were hospitalised due to CHD
(ICD-10 codes: I20-I25 as a primary or secondary diagno-
sis), cerebrovascular diseases or transient ischaemic attack
(I60-I66, I68-I69, G45-G46), atherosclerosis (I70), aneur-
ysm (I71) or any medical procedure related to CHD
(coronary artery bypass graft (CABG), or percutaneous
transluminal coronary angioplasty (PTCA)), cerebrovascu-
lar diseases (carotid endarterectomy or thrombolytic
therapy), or peripheral artery disease and/or purchased
nitrates (ATC class: C01DA) during the 3 years prior to
statin initiation; and/or who were entitled to higher medi-
cation reimbursement due to chronic CHD at statin initi-
ation (see online supplementary table S1). We excluded
also patients who had purchased lipid modifying medica-
tions other than statins within 3 years prior to statin initi-
ation. Patients who died or were institutionalised or had
an outcome event within the first year after statin initi-
ation were excluded. The flow chart of the cohort com-
position is presented in figure 1.
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The outcome follow-up started 1 year after the statin
initiation (figure 2) because computation of adherence
for time periods shorter than 1 year may be unstable,19
and to exclude early outcomes that occurred before the
therapeutic response to statin therapy could be estab-
lished.20–24 The follow-up lasted up to 3 years (from 12
to 48 months after statin initiation). We followed patients
until they experienced the outcome of interest, died,
were long-term institutionalised (adherence cannot be
defined during the long-term care) or 48 months was
reached, whichever occurred first.
Adherence to statin therapy
Statin adherence was measured from the Finnish
Prescription Register as PDC19 25 at 1-year intervals since
statin initiation (figure 2). Using a validated dosage
assumption of one tablet per day,26 we calculated the
number of days covered by dispensed statin tablets
during each 1-year period and divided it by 365. When a
refill overlapped with the previous dispensing, the new
dispensing was assumed to start the day after the end of
the prior dispensing. Switching between statins was con-
sidered as a continuation of therapy. Denominators were
corrected for days in hospital because medications
during hospitalisation are provided by the service pro-
vider. Finally, women were classified as adherent or non-
adherent by applying the conventional cut-off value of
PDC ≥80%.27 28
Outcomes
The outcome was a composite of an acute cardiovascular
event defined as a hospitalisation for an acute coronary
syndrome (ACS) (ICD-10 codes: I20.0, I21-I22) or an
acute ischaemic stroke (I63) as a primary diagnosis in
the Finnish Care Register (see online supplementary
table S2).
Confounders
In the construction of inverse probability of treatment
weights (IPTWs), adherence models should include
common causes of adherence and outcome (confoun-
ders), and pure risk factors.29 30 After reviewing the lit-
erature23 and receiving expert opinions about
associations with the outcome, we identified several
potential confounders. Directed acyclic graphs were
used to describe the relationships between adherence,
outcome events and confounders (figure 3) when
making decisions about the need for adjustments in the
statistical analyses.
Baseline confounders measured prior to or at statin
initiation included sociodemographic and socio-
economic factors, type and intensity of the initial statin
therapy (modified from Stone et al31), year of statin initi-
ation, cardiac comorbidity factors (such as diabetes,
hypertensive diseases, heart failure/chronic cardiac
insufficiency, cardiac arrhythmias, dysfunctions of lipid
metabolism, number of cardiovascular medications in
use and Charlson Comorbidity Index32) and non-cardiac
comorbidity factors (such as rheumatoid arthritis and
depression). Detailed definitions and classifications of
baseline confounders are presented in online supple-
mentary table S3.
After statin initiation, we measured cardiac and non-
cardiac confounders as well as marital status, income,
labour market status and any increase in the intensity of
statin therapy on an annual basis. In addition, we
treated chronic forms of atherosclerotic CVD, such as
chronic CHD, CABG/PTCA, chronic cerebrovascular
disease or transient ischaemic attack, atherosclerosis and
use of nitrates, appearing after statin initiation as time-
dependent confounders. Detailed definitions and classi-
fications of time-dependent confounders are presented
in online supplementary table S4.
Statistical modelling
We compared the results from conventional discrete-
time hazards models with those estimated from MSMs.
Both models were estimated with a pooled log-binomial
regression model to produce a collapsible effect
measure33 for the comparison purpose (conditional vs
marginal effect estimate). Outcome was assessed at
monthly intervals so that each person-month was treated
as an observation. First, we examined a discrete-time
hazards model with time dependent dichotomous
adherence to produce a crude HR (model 1) for the
effect of statin adherence on acute cardiovascular
events. Next, we adjusted the crude effect estimate for
baseline confounders (model 2). Finally, we used MSMs
to adjust for time-dependent confounding affected by
prior adherence.17 In MSMs, the study population is
weighted to produce a pseudo-population in which con-
founders are balanced between the adherence groups,
Figure 1 Flow chart of the cohort of women initiating statins
for primary prevention of cardiovascular disease.
Lavikainen P, et al. BMJ Open 2016;6:e011306. doi:10.1136/bmjopen-2016-011306 3
Open Access
but the causal effect of the adherence on the outcome
is preserved.17
We derived year-specific IPTWs for MSMs by applying
logistic regression models as adherence models to esti-
mate each individual’s probability of having the observed
adherence at three time points; at 12, 24 and 36 months
since statin initiation (figure 2). At 12 months after
statin initiation, we calculated IPTW as an inverse prob-
ability of the observed first-year adherence conditional
on baseline confounders. The IPTW was stabilised with
the prevalence of observed first-year adherence to
increase the precision of the MSM estimator (see online
supplementary appendix 1). At 24 and 36 months after
statin initiation, the inverse probability of adherence
observed over the previous year was calculated condi-
tional on adherence history, baseline confounders, and
lagged time-dependent confounders that were measured
prior to that adherence assessment period (figure 3) to
ensure conditioning only on prior values of confoun-
ders.34 At 24 and 36 months after statin initiation, the
probabilities of observed adherences conditional on
adherence histories were used to stabilise the inverse
probabilities. The stabilised IPTWs at 24 and 36 months
after statin initiation were calculated cumulatively by
multiplying the stabilised inverse probabilities from pre-
vious time points up to the specific time point. The bal-
ancing properties of the stabilised IPTWs were checked
by using standardised difference (SD) to compare con-
founder distributions between the two adherence
groups in each of the yearly periods. An SD value >0.1
was considered as an indication of a meaningful differ-
ence between the groups.35
MSMs were estimated using pooled log-binomial
regression models weighted with stabilised IPTWs for
person-month data (see online supplementary appen-
dix 1). We examined the average causal effect of adher-
ence (PDC ≥80%) versus non-adherence (PDC <80%)
during the previous adherence ascertainment year on the
hazard of acute cardiovascular events using MSM (model
3). To test the robustness of our results against extreme
weights, we examined the effect of truncating32 the stabi-
lised IPTWs at the 1st and 99th centiles (model 4).
Figure 3 Directed acyclic graph for time-dependent
adherence and confounding structure. B, baseline
characteristics; A12–A36, time-dependent adherences
measured at months 12, 24 and 36; L12–L24, time-dependent
confounders measured at months 12 and 24; Y, outcome.
Figure 2 Schematic study design.
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We performed several sensitivity analyses. First, we
used time-dependent confounders measured simultan-
eously with adherence in adherence models to demon-
strate the impact of the miss-specified time sequence on
the effect estimate (see online supplementary appendix
2 and figure S1 for more information on sensitivity ana-
lyses). Second, we added medical procedures (CABG/
PTCA) and death from any cause into the composite
outcome to evaluate the effect of potential selection bias
as these events may be viewed as competing risks.36
Third, we compared patients who had at least once
refilled their statin prescription (at least slight adher-
ence) to those with no refills after the first dispensation
(extreme non-adherence) (see online supplementary
appendix 2 and figure S2). We assumed that patients
with only the initial dispensation during the follow-up
would mimic those with the same indication but no
statin exposure, that is, a placebo group in randomised
controlled trials.
Finally, we wanted to evaluate the healthy-adherer
effect as an alternative explanation for our observations
(models 5 and 6).15 For that, we used low-energy frac-
tures as a negative control outcome that could reflect
unhealthy behaviours, but is unrelated to statin effect.37
Fractures were identified as the first hospital visit for a
low-energy fracture of hip (ICD-10 codes S32.1-S32.4,
S72.0-S72.8 as a primary or secondary diagnosis), wrist
(S52.0, S62.4), ankle (S82.1-S82.7, S92.0, S92.3), or
forearm (S42.2-S42.4) (see online supplementary table
S2). We used the same adherence models as in models 3
and 4 to derive IPTWs for MSM.
The analyses were performed using SAS software V.9.4
(SAS Institute Inc, Cary, North Carolina, USA), see SAS
syntax for the primary analysis in online supplementary
appendix 1. Missing values in variables measured after
statin initiation (120.03% patients missed data on both
marital status and labour market status) were imputed
with the last observation carried forward technique.
RESULTS
We identified 52 215 women aged 45–64 years who
initiated statin therapy during 2001–2004. After exclu-
sions, our final cohort consisted of 42 807 women
(figure 1). The mean age was 56.2 years (SD: 4.9) and
53.0% were adherent to statin therapy (PDC ≥80%)
during the first year after initiation (table 1). Baseline
confounders were well balanced between the adherent
and non-adherent women (table 1 and online supple-
mentary table S5). The mean PDC was 94.0% among
adherers, and 43.7% among non-adherers during the
first assessment year. Of those who were adherent during
the first year, 76.0% remained adherent in the second
year, and 63.8% remained in this state for 3 years. Of
the non-adherers during the first year, 84.5% remained
non-adherent for 2 years and 73.7% for 3 years after
statin initiation (figure 2). At baseline, agents acting on
the renin-angiotensin system were being used by 26.4%
of the women, β blocking agents by 25.8%, diuretics by
13.0%, calcium channel blockers by 11.2% and antith-
rombotic agents by 1.8%.
During the follow-up, 470 women experienced an
acute cardiovascular event (ACS, n=256, or acute
Table 1 Selected baseline characteristics according to
adherence during the first adherence ascertainment year
Non-adherers
(PDC <80%)
(n=20 120)
Adherers
(PDC ≥80%)
(n=22 687)
n
Per
cent n
Per
cent SD
Age, years
45–49 2423 12.0 2238 9.9 0.070
50–54 5286 26.3 5409 23.8 0.056
55–59 6621 32.9 7949 35.0 0.045
60–64 5790 28.8 7091 31.3 0.054
Statin at baseline
Simvastatin 7801 38.8 8768 38.7 0.003
Lovastatin 373 1.9 337 1.5 0.029
Pravastatin 1421 7.1 1046 4.6 0.105
Fluvastatin 1485 7.4 1818 8.0 0.024
Atorvastatin 7147 35.5 8095 35.7 0.003
Rosuvastatin 1893 9.4 2623 11.6 0.070
Intensity of statin therapy
Low* 5954 29.6 7114 31.4 0.038
Moderate† 14 057 69.9 15 512 68.4 0.032
High‡ 109 0.5 61 0.3 0.043
Diabetes 2040 10.1 2732 12.0 0.061
Insulin 605 3.0 765 3.4 0.021
Hypertensive
diseases
5246 26.1 6485 28.6 0.056
Number of concurrent CVD medications
0 10 443 51.9 10 812 47.7 0.085
1 5470 27.2 6682 29.5 0.050
2 3078 15.3 3781 16.7 0.037
3–6 1129 5.6 1412 6.2 0.026
Depression 2624 13.0 3089 13.6 0.017
Respiratory
diseases
3418 17.0 3502 15.4 0.042
Hormone
therapy
7654 38.0 9398 41.4 0.069
Total number of concurrent medications
1–2 7085 35.2 7289 32.1 0.065
3–5 7202 35.8 8037 35.4 0.001
6–31 5833 29.0 7361 32.5 0.077
Number of in-hospital days
0 12 193 60.6 14 222 62.7 0.043
1–2 3902 19.4 4099 18.1 0.034
3–7 2656 13.2 2825 12.5 0.022
8–321 1369 6.8 1541 6.8 0.000
Charlson Comorbidity Index
≥1 1307 6.5 1583 7.0 0.019
*Fluvastatin 20–40 mg, lovastatin 20 mg, pravastatin 10–20 mg,
simvastatin 5–10 mg.
†Atorvastatin 10–20 mg, fluvastatin 80 mg, lovastatin 40 mg,
pravastatin 40 mg, rosuvastatin 10 mg, simvastatin 20–40 mg.
‡Atorvastatin 40–80 mg, rosuvastatin 20–40 mg, simvastatin
80 mg.
CVD, cardiovascular disease; PDC, proportion of days covered;
SD, standardised difference.
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ischaemic stroke, n=214) (figure 2). The study popula-
tion produced 753 796 adherent person-months and
770 826 non-adherent person-months with 208 and 262
acute cardiovascular events. Discrete-time hazards model
with time-dependent adherence and time as predictors
resulted in a crude HR of 0.82 (95% CI 0.68 to 0.98) for
the effect of adherence on acute cardiovascular events
(model 1, table 2). When the model was adjusted for
baseline confounders, HR decreased to 0.76 (95% CI
0.63 to 0.91) (model 2, table 2).
The estimated HR of the MSM was 0.78 (95% CI 0.65
to 0.94); thus, an average of 22% reduction in the hazard
of acute cardiovascular events had all the women
remained adherent during the previous adherence ascer-
tainment year when compared with if all of them had
stayed non-adherent (model 3, table 2). According to SD
values, the ability of the stabilised IPTWs to balance the
baseline and time-dependent confounders between
adherers and non-adherers was good (see online supple-
mentary table S6). The means of the stabilised IPTWs
were equal to 1 (table 3). In order to eliminate the effect
of observations with extreme weights, we truncated the
stabilised IPTWs at the 1st and 99th centiles (range of
the truncated stabilised IPTWs: 0.66, 1.59); this did not
alter the estimation results (model 4, table 2).
In the sensitivity analyses, replacing time-dependent
confounders that were measured prior to the adherence
assessment period with the values measured concur-
rently with adherence in the adherence models reduced
the HR estimate to 0.74 (95% CI 0.61 to 0.89) (see
online supplementary appendix 2 and table S7).
Addition of CABG/PTCA and death from any cause to
the composite outcome resulted in a HR 0.79 (95% CI
0.69 to 0.90) when estimated with the MSM (see online
supplementary appendix 2 and table S7). Those women
who were at least slightly adherent (refilled once or
more) had a potentially reduced risk of acute cardiovas-
cular events (HR: 0.85, 95% CI 0.62 to 1.16) when com-
pared with extremely non-adherent patients (no refills)
when estimated with MSMs (see online supplementary
appendix 2 and table S8).
Lastly, the causal effect of adherence to statins on low-
energy fractures was explored. Among 42 301 women
without low-energy fractures within 3 years prior to statin
initiation as well as during the first adherence ascertain-
ment year, 557 suffered a low-energy fracture during the
3-year follow-up. Statin adherers had a potentially
reduced risk of experiencing fractures compared with
non-adherers when estimated with the MSM (HR: 0.90,
95% CI 0.76 to 1.07).
Table 2 Effect of statin adherence on the hazard of an acute cardiovascular event
Adherents vs
non-adherents
Model Type of model Variables in adherence model Variables in outcome model HR 95% CI
1 Discrete-time hazards
model
Not applicable Time-dependent adherence 0.82 0.68 to 0.98
2 Discrete-time hazards
model
Not applicable Time-dependent adherence
and baseline confounders*
0.76 0.63 to 0.91
3 MSM Adherence history, baseline* and
lagged time-dependent†
confounders
Adherence during the
previous assessment year
0.78 0.65 to 0.94
4 MSM, weights truncated
at 1st and 99th centiles
Adherence history, baseline* and
lagged time-dependent†
confounders
Adherence during the
previous assessment year
0.78 0.65 to 0.94
*Baseline confounders as presented in online supplementary table S5.
†Lagged time-dependent confounders: marital status, income, labour market status, increase in intensity of statin therapy, diabetes, use of
insulin, hypertensive diseases, heart failure or chronic cardiac insufficiency, cardiac arrhythmia, dysfunctions of lipid metabolism, number of
concurrent cardiovascular medications, Charlson Comorbidity Index, chronic CHD, chronic CHD hospitalisation, medical procedure related to
CHD, chronic cerebrovascular diseases and transient ischaemic attack, atherosclerosis, use of nitrates, rheumatoid arthritis, cancer, mental
disorders, depression, respiratory diseases, alcohol-related diseases, use of non-steroidal anti-inflammatory medications, anxiolytics,
hypnotics and sedatives, corticosteroids for systemic use, and hormone therapy, total number of concurrent medications, number of
in-hospital days.
CHD, coronary heart disease; MSM, marginal structural model.
Table 3 Year-specific distributions of stabilised inverse probability of treatment weights
Time since statin initiation (months) Mean Median Minimum Maximum 1st centile 99th centile
12 1.00 0.98 0.57 3.02 0.72 1.47
24 1.00 0.97 0.17 10.47 0.68 1.57
36 1.00 0.97 0.15 11.24 0.62 1.67
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DISCUSSION
When applying MSM methodology, we detected a 22%
reduction in the hazard of acute cardiovascular events if
every woman had been adherent to statins as compared
to them being non-adherent. The result was robust
against different specifications of statistical models
applied. In our study, measured time-dependent con-
founding was obviously not strong because MSMs
accounting for it produced effect estimates which were
of the same magnitude as the estimates from conven-
tional analyses after adjusting only for baseline confoun-
ders. Measured baseline confounding was not
particularly strong either as the crude HR was very close
to the adjusted HRs.
Earlier studies on the relationship between statin
adherence and CVD in primary prevention populations
have attempted to account for time-dependent con-
founding by occurrence of other forms of CVD2–5 or
changes in the intensity of statin therapy4 6 during the
follow-up (table 4). They have measured adherence and
time-dependent confounders at the same time point,
and potentially induced bias in the causal analysis.
Adjustment for intermediate variables along the causal
pathway in addition to different definitions for adher-
ence, outcomes and populations in primary prevention
(table 4) may be reasons for the differences in the esti-
mated reductions in the event incidence when com-
pared to our results.10 In our study, addition of
time-dependent confounders measured simultaneously
with adherence (ie, intermediate variables) to the adher-
ence models for MSM produced a slightly stronger asso-
ciation between adherence and acute cardiovascular
events (HR: 0.74, 95% CI 0.61 to 0.89) than our original
MSM (HR: 0.78, 95% CI 0.64 to 0.93). In the presence
of unmeasured predictors that are causes both for an
intermediate variable and the outcome, conditioning on
the intermediate variable may open a non-causal path
between adherence and the outcome and may, thereby,
create an additional association.10 38 Thus, due to adjust-
ment for intermediate variables, the apparent effect may
be weaker or stronger than the true effect.
In the comparison between individuals who were
slightly adherent with the extremely non-adherent, we
observed a potential but non-significant effect (HR:
0.85, 95% CI 0.62 to 1.16) on the hazard of acute car-
diovascular events. This observed effect for statins is rea-
sonable in comparison with the results emerging from
primary prevention trials (risk ratios 0.67 for non-fatal
myocardial infarction, and 0.69 for non-fatal stroke over
a maximum of 5.3 years of follow-up39) as the average
adherence level among those with at least one refill was
most likely lower than adherence levels in these con-
trolled trials.
Our study has several strengths. First, we expanded on
the previous studies by accounting for time-dependent
confounding affected by previous adherence in addition
to the time dependence of adherence.40 Specifically, we
used lagged time-dependent confounders in the IPTW
construction to ensure that we had a proper time
sequence. Adherence was measured as PDC in yearly
periods and dichotomised using 80% as a cut-off value.
Although the method improved measurement of adher-
ence compared to the earlier studies, where adherence
was typically measured as a fixed value throughout the
follow-up,2–7 it produced rough estimates. Recently,
Bijlsma et al41 extended the PDC method to quantify
adherence in the time intervals between consecutive
prescriptions, and the method was shown to produce
more precise estimates compared with a fixed-time PDC
measure. Second, as both medical procedures related to
CHD and death from any cause can be regarded as a
competing risk for acute cardiovascular events, we
formed a new composite end point for the sensitivity
analysis to account for the potential selection bias35 and
observed that these competing risks did not contribute
appreciably to the bias. Finally, we used low-energy frac-
tures as a negative control outcome, and observed a
10%, non-significant reduction in the hazard of fractures
suggesting that part of the observed effect of statin
adherence on acute cardiovascular events may be due to
the healthy-adherer effect. It is noteworthy, however, that
unmeasured confounding by body mass index may have
changed the HRs for fractures and CVD events in oppos-
ite directions: being overweight and obesity seem to
improve statin adherence,42 and are known to lower frac-
ture risk.43 However, these may increase the risk of
CHD.44 Other approaches to adjust effect estimates for
unmeasured confounding include, for example, integra-
tion of validation data45 and instrumental variable ana-
lysis.46 In our recent study,8 healthy-adherer effect was
examined using propensity score calibration with an
external validation study to adjust for selected lifestyle
factors (body mass index, smoking, alcohol use, physical
activity) and self-reported health. However, no major
effect on the effect estimate was found. Finally, conduct-
ing a randomised controlled trial would guarantee
exchangeability between the groups at baseline, but the
design is not feasible for examining the effects of medi-
cation adherence.47
Yet we may have introduced selection bias when condi-
tioning on survival plus remaining non-institutionalised
and free of outcomes during the first adherence ascer-
tainment year.48 There may be factors such as poor
health status that lead to both early exclusion and are
independent risk factors for acute cardiovascular events.
Statin therapy and thus adherence to this therapy,
however, is not likely to have appreciably affected
the CVD event risk or survival during the first year of
use.20–24 Furthermore, we did not attempt to adjust for
potentially differential loss to follow-up due to long-term
institutionalisation because the proportion of patients
institutionalised was low (0.3%). Our adherence
measure assumes that PDC corresponds to the propor-
tion of days of medication use, but we could not
confirm whether dispensed statins were actually con-
sumed. Acute cardiovascular events were captured from
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Table 4 Population-based studies on the effect of statin adherence on cardiovascular morbidity in primary prevention of cardiovascular disease that have adjusted for
time-dependent confounding
Country, design,
study population
Max follow-up
(years)
Exposure
definition
Exposure
classification
Time-dependent
confounders Outcome
Crude effect
estimate (95% CI)
Adjusted effect
estimate (95% CI)
Canada2
(n=12 180), nested
case–control, 50–
64 years, 65% ♀
3.5 PDC from statin
initiation to time
of outcome
≥90%
<90%
Cardiac comorbidities
measured during the
follow-up
Non-fatal CHD after
1st year of follow-up
RR 0.84 (not reported)
1.00
RR 0.81 (0.67 to 0.97)
1.00
Canada3
(n=147 601),
nested case–
control, 45–
85 years, 63% ♀
6.5 MPR from
statin initiation
to time of
outcome
≥80%
60–79%
40–59%
20–39%
<20%
Cardiac and non-cardiac
comorbidities and
medication use measured
during the follow-up
Non-fatal CHD or
all-cause death after
1st year of follow-up
RR 0.90 (0.85 to 0.96)
0.92 (0.85 to 1.00)
0.94 (0.86 to 1.02)
0.95 (0.87 to 1.04)
1.00
RR 0.82 (0.77 to 0.87)
0.85 (0.78 to 0.92)
0.87 (0.80 to 1.00)
0.91 (0.84 to 1.01)
1.00
Canada4
(n=41 140), nested
case–control, 45–
85 years, 63% ♀
6.5 MPR from
statin initiation
to time of
outcome
≥80%
60–79%
40–59%
20–39%
<20%
Cardiac and non-cardiac
comorbidities measured
during the follow-up
Non-fatal
cerebrovascular
disease after 1st year
of follow-up
RR 0.83 (0.74 to 0.93)
0.93 (0.80 to 1,07)
0.90 (0.76 to 1.06)
1.01 (0.86 to 1.19)
1.00
RR 0.74 (0.65 to 0.84)
0.82 (0.71 to 0.96)
0.83 (0.70 to 0.98)
0.97 (0.83 to 1.15)
1.00
Italy5 (n=90 832),
cohort, ≥18 years
(mean 62 years),
59% ♀
6 PDC from statin
initiation to time
of each
outcome
>75%
51–75%
26–50%
≤25%
Concomitant cardiac
medication use, and
switching of statins
measured during the
follow-up
Non-fatal CHD after
1st year of follow-up
HR 0.97 (0.85 to 1.12)
0.90 (0.79 to 1.04)
0.86 (0.75 to 0.99)
1.00
HR 0.81 (0.71 to 0.94)
0.82 (0.71 to 0.95)
0.85 (0.72 to 0.98)
1.00
Israel6 (n=171 535),
cohort, 45–
75 years, 58% ♀
12 MPR from
statin initiation
to time of
outcome
≥80%
60–79%
40–59%
20–39%
<20%
Efficacy of statin therapy
measured during the
follow-up
Non-fatal CHD or
stroke after 1st year
of follow-up
Not reported HR 0.64 (0.60 to 0.67)
0.63 (0.59 to 0.67)
0.71 (0.67 to 0.75)
0.90 (0.85 to 0.96)
1.00
CHD, coronary heart disease; MPR, medication possession ratio; PDC, proportion of days covered; RR, rate ratio.
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primary discharge diagnoses in the Finnish Care
Register. Validation studies of the register have reported
a positive predictive value of 80% for ischaemic stroke
among women aged 25 years and older during the years
1993–1998, and that of 69% for ACS among women
aged 35–74 years during 1998–2002 when compared
with the Finnish population-based stroke and myocardial
infarction registers.49 50 The temporal distance between
the observed adherence and outcomes of interest was
between 1 and 365 days. It is possible that the risk of
outcome has been affected by changes in the adherence
level during the outcome assessment period.
Furthermore, our study population consisted of women
who initiated statin use in the early 2000s. Subsequently,
there has been a shift towards more intensive statin
therapy leading to potentially larger relative benefits
associated with adherence.28 Lastly, MSM assumes no
unmeasured confounding, but we had no data on some
important confounders, such as cholesterol level, blood
pressure, smoking or family history of CVD. However, we
were able to adjust for presence of the most severe
forms of hypertension and dyslipidemia leading to hos-
pitalisation or entitlement to special reimbursement,
which may have partly controlled for confounding by
cholesterol and blood pressure levels.
CONCLUSIONS
This paper supports the earlier results of the beneficial
effect of sufficient adherence to statin therapy for
patients in primary prevention of CVD. We also showed
that accounting for the confounding factors on the
causal pathway correctly did not appreciably change this
result, presumably because time-dependent confound-
ing was not strong.
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